Clinical Trial

Plasma Oxytocin Response to Oral Estrogens in Healthy Controls and AVP-Deficiency

Study acronym: PHOENIX
Recruiting
View on ClinicalTrials.gov →
Summary
The PHOENIX study aims to investigate whether oral estradiol valerate (EV) and ethinylestradiol (EE) can stimulate oxytocin (OXT) and neurophysin-1 (NP-1) release in humans. The goal is to assess their potential as a safe diagnostic stimulation test for oxytocin deficiency, particularly in patients with arginine vasopressin (AVP) deficiency.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-01-14.
Trial Details
NCT Number NCT07361263
Lead Sponsor University Hospital, Basel, Switzerland
Conditions AVP Deficiency, Diabetes Insipidus
Enrollment 28 participants
Start Date 2026-01-09
Primary Completion 2027-02 (estimated)
Study Completion 2027-02 (estimated)
Updated on ClinicalTrials.gov 2026-08-11